User login
WASHINGTON — The dietary supplement chondroitin sulfate significantly reduced the progression of joint space narrowing among patients with knee osteoarthritis in a multicenter, prospective, double-blind study presented in a late-breaking abstract session at the annual meeting of the American College of Rheumatology.
This radiologic finding represents a structure-modifying effect in the clinical progression of the disease, according to Dr. Jean-Yves Reginster, who has an unspecified interest in the Institut Biochimique SA (Pambio-Noranco, Switzerland), the manufacturer of Chondrosulf, the chondroitin formulation used in the study.
The 2-year Study on Osteoarthritis Progression Prevention (STOPP) included 622 patients with mild to moderate osteoarthritis from 40 centers in Europe and the United States, randomizing them to receive oral chondroitin sulfate, 800 mg/day or placebo.
Rescue acetaminophen and nonsteroidal anti-inflammatory drugs were permitted.
All had tibiofemoral knee osteoarthritis evaluated for pain on a visual analog scale and radiologically on digital x-rays utilizing a high-performance Lyon schuss slightly modified semiflexed view. The minimal level of pain for inclusion was 33 mm for the past 3 months, and the minimum joint space was greater than 1 mm at the narrowest point.
Patients ranged in age from 45 to 80 years, and with a mean body mass index of 29 kg/m
If both knees were affected, the more severely affected knee was chosen as the index joint.
There were 206 completers in both groups. In an intention-to-treat analysis of the primary outcome measure—joint space narrowing at the medial compartment of the knee over 24 months—a significantly greater mean joint space narrowing of 0.24 mm was seen among patients receiving placebo, compared with 0.10 mm among those receiving chondroitin, reported Dr. Reginster of the University of Liège (Belgium).
The change in joint space was linear among patients receiving placebo, around 0.1 mm/year, which was prevented completely in patients receiving chondroitin sulfate, he said.
“The final difference was 55% prevention in joint space narrowing, which was statistically significant at the end of the second year,” he added.
Significant differences also were seen in pain scores on VAS and on the Western Ontario and McMaster Universities osteoarthritis index scores (WOMAC). The chondroitin group also used 20% fewer NSAIDs, compared with the placebo group, he said.
WASHINGTON — The dietary supplement chondroitin sulfate significantly reduced the progression of joint space narrowing among patients with knee osteoarthritis in a multicenter, prospective, double-blind study presented in a late-breaking abstract session at the annual meeting of the American College of Rheumatology.
This radiologic finding represents a structure-modifying effect in the clinical progression of the disease, according to Dr. Jean-Yves Reginster, who has an unspecified interest in the Institut Biochimique SA (Pambio-Noranco, Switzerland), the manufacturer of Chondrosulf, the chondroitin formulation used in the study.
The 2-year Study on Osteoarthritis Progression Prevention (STOPP) included 622 patients with mild to moderate osteoarthritis from 40 centers in Europe and the United States, randomizing them to receive oral chondroitin sulfate, 800 mg/day or placebo.
Rescue acetaminophen and nonsteroidal anti-inflammatory drugs were permitted.
All had tibiofemoral knee osteoarthritis evaluated for pain on a visual analog scale and radiologically on digital x-rays utilizing a high-performance Lyon schuss slightly modified semiflexed view. The minimal level of pain for inclusion was 33 mm for the past 3 months, and the minimum joint space was greater than 1 mm at the narrowest point.
Patients ranged in age from 45 to 80 years, and with a mean body mass index of 29 kg/m
If both knees were affected, the more severely affected knee was chosen as the index joint.
There were 206 completers in both groups. In an intention-to-treat analysis of the primary outcome measure—joint space narrowing at the medial compartment of the knee over 24 months—a significantly greater mean joint space narrowing of 0.24 mm was seen among patients receiving placebo, compared with 0.10 mm among those receiving chondroitin, reported Dr. Reginster of the University of Liège (Belgium).
The change in joint space was linear among patients receiving placebo, around 0.1 mm/year, which was prevented completely in patients receiving chondroitin sulfate, he said.
“The final difference was 55% prevention in joint space narrowing, which was statistically significant at the end of the second year,” he added.
Significant differences also were seen in pain scores on VAS and on the Western Ontario and McMaster Universities osteoarthritis index scores (WOMAC). The chondroitin group also used 20% fewer NSAIDs, compared with the placebo group, he said.
WASHINGTON — The dietary supplement chondroitin sulfate significantly reduced the progression of joint space narrowing among patients with knee osteoarthritis in a multicenter, prospective, double-blind study presented in a late-breaking abstract session at the annual meeting of the American College of Rheumatology.
This radiologic finding represents a structure-modifying effect in the clinical progression of the disease, according to Dr. Jean-Yves Reginster, who has an unspecified interest in the Institut Biochimique SA (Pambio-Noranco, Switzerland), the manufacturer of Chondrosulf, the chondroitin formulation used in the study.
The 2-year Study on Osteoarthritis Progression Prevention (STOPP) included 622 patients with mild to moderate osteoarthritis from 40 centers in Europe and the United States, randomizing them to receive oral chondroitin sulfate, 800 mg/day or placebo.
Rescue acetaminophen and nonsteroidal anti-inflammatory drugs were permitted.
All had tibiofemoral knee osteoarthritis evaluated for pain on a visual analog scale and radiologically on digital x-rays utilizing a high-performance Lyon schuss slightly modified semiflexed view. The minimal level of pain for inclusion was 33 mm for the past 3 months, and the minimum joint space was greater than 1 mm at the narrowest point.
Patients ranged in age from 45 to 80 years, and with a mean body mass index of 29 kg/m
If both knees were affected, the more severely affected knee was chosen as the index joint.
There were 206 completers in both groups. In an intention-to-treat analysis of the primary outcome measure—joint space narrowing at the medial compartment of the knee over 24 months—a significantly greater mean joint space narrowing of 0.24 mm was seen among patients receiving placebo, compared with 0.10 mm among those receiving chondroitin, reported Dr. Reginster of the University of Liège (Belgium).
The change in joint space was linear among patients receiving placebo, around 0.1 mm/year, which was prevented completely in patients receiving chondroitin sulfate, he said.
“The final difference was 55% prevention in joint space narrowing, which was statistically significant at the end of the second year,” he added.
Significant differences also were seen in pain scores on VAS and on the Western Ontario and McMaster Universities osteoarthritis index scores (WOMAC). The chondroitin group also used 20% fewer NSAIDs, compared with the placebo group, he said.